期刊文献+

Experimental study on the protective effect of Chinese medicine Ruanganyin on the liver of HBV transgenic mice

下载PDF
导出
摘要 Objective: To study the protective effect of ruanganyin on the liver of HBV transgenic mice. Methods: 50 half HBV transgenic mice, male and female, were randomly divided into treatment group (high, medium and low dose Ruanganyin), model group, positive control group (entecavir dispersible tablet) and 10 non HBV transgenic mice as blank control. The mice were killed after 4 weeks of drug intervention.The serum levels of ALT, AST, TBIL, LN, HA, IV-C and PCIII were observed. Results: (1) compared with the blank control group, the ALT,AST and TBIL levels in the model group were significantly higher than those in the blank control group (P < 0.01);compared with the model group, the ALT, AST and TBIL levels in the high-dose group of ruanganyin after treatment were significantly lower than those in the model group (P<0.01/P<0.05);the ALT, AST and TBIL levels in the positive control group were lower than those in the model group (P<0.01/P<0.05) There was no significant difference in ALT, AST and TBIL levels between the two groups (P>0.05). (2) Compared with the blank control group, the level of LN, HA, IV-C and PCIII in the model group was significantly higher than that in the blank control group (P<0.01);compared with the model group, the level of LN, HA and IV-C in the high-dose group and the positive control group after treatment was significantly lower than that in the model group (P<0.01);the level of PCIII in the high-dose group and the positive control group after treatment was significantly lower than that in the model group (P<0.01);There was no significant difference in LN, HA, IV-C and PCIII levels between the two groups (P> 0.05). Conclusion: Chinese medicine Ruanganyin has the effects of protecting liver, reducing enzyme and anti fibrosis, but its mechanism of anti fibrosis needs further study.
出处 《Journal of Hainan Medical University》 2020年第3期1-4,共4页 海南医学院学报(英文版)
基金 NSFC project(81874451).
  • 相关文献

参考文献8

二级参考文献109

  • 1吴桂甫,王柳萍,凌兰,杨小叶,杨斌.莪术对大鼠缺血性脑中风的治疗作用及其机制研究[J].中药与临床,2013,4(6):34-36. 被引量:7
  • 2黄可儿,赵敏,王建华.黄芪总苷的药理研究进展[J].中药新药与临床药理,2005,16(6):461-463. 被引量:34
  • 3卢林耿,王中民,张永祥,朱全胜,尤银珍.对四氯化碳所致大鼠肝脏损伤机制的研究[J].中西医结合肝病杂志,1996,6(2):24-25. 被引量:16
  • 4汪涛,姜华,陆国才,袁伯俊,佘佳红.四氯化碳肝脏毒性机制的研究进展[J].毒理学杂志,2007,21(4):338-339. 被引量:22
  • 5Kitamura Y,Ninomiya H.Smad expression of hepatic stellate cells in liver cirrhosis in vivo and hepatic stellate cell line in vitro.Pathol Int,2003,53:18-266.
  • 6Bresalier RS,Ho SB,Schoeppner HL,Kim YS,SleisengermH,Brodt P,Byrd JC.Enhanced sialylation ofmucin-associated carbohydrate structures in human colon cancermetastasis[J].Gastroenterology,1996,110:1354-1367.
  • 7Cui X,Shimizu I,Lu G,Itonagam,Inoue H,Shonom,Tamaki K,Fukuno H,Ueno H,Ito S.Inhibitory effect of a soluble transforming growth factor beta type Ⅱ receptor on the activation of rat hepatic stellate cells in primary culture[J].J Hepatol,2003,39:731-737.
  • 8Friedman SL.Liver fibrosis-from bench to bedside[J].J Hepatol 2003,38(Suppl):S38-53.
  • 9Reeves HL,Friedman SL.Activation of hepatic stellate cells-a key issue in liver fibrosis[J].Front Biosc,2002,7:d808-826.
  • 10Gressner AM,Weiskirchen R.Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta asmajor players and therapeutic targets[J].J Cellmolmed,2006,10:76-99.

共引文献208

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部